All In Biotech

Drug Trial Radar · NCT06475781

Study to Evaluate Safety and Efficacy of Mirivadelgat in PH-ILD (Windward)

A Multinational Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety and Efficacy of Mirivadelgat, an Aldehyde Dehydrogenase 2 Activator, in Patients With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 126 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

126

Planned (sponsor's estimate)

Start

Mar 1, 2025

Primary completion

Feb 2028

Study completion Feb 2028

Sponsor

Sponsor type
Industry
Collaborators
QPS Holdings LLC
First posted
Jun 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to see if mirivadelgat will work in participants with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD). It will also learn about the safety of mirivadelgat. The main question it aims to answer is if mirivadelgat will improve pulmonary vascular resistance (PVR). Pulmonary vascular resistance is a way to measure blood flow in the lungs. Researchers will compare mirivadelgat to a placebo (a look-alike capsule that contains no drug) to see if mirivadelgat works to improve the symptoms of PH-ILD. The symptoms of PH-ILD that are being looked at are exercise tolerance, heart function, and general well-being. Participants will: Take mirivadelgat or a placebo once a day for 12 weeks Visit the clinic once every 4 weeks for checkups and tests Receive phone calls every one or two weeks to check on how things are going

Conditions

  • Group 3 Pulmonary Hypertension

Interventions

  • MirivadelgatDrug

    Selective aldehyde dehydrogenase 2 (ALDH2) activator

  • placeboDrug

    placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pulmonary Vascular Resistance (PVR)Time frame: 12 weeks

Locations

15 sites in 3 countries. Site status is shown where the registry gives one.

  • University Clinical Centre of the Republic of Srpska

    Banja Luka, Bosnia and Herzegovina · Not yet recruiting

  • Clinical Center of the University of Sarajevo

    Sarajevo, Bosnia and Herzegovina · Not yet recruiting

  • Acad. G Chapidze Emergency Cardiology Center LLC

    Tbilisi, Georgia · Recruiting

  • JSC Viani - Iv. Bokeria University Hospital

    Tbilisi, Georgia · Recruiting

  • LTD Open Heart - University Hospital

    Tbilisi, Georgia · Recruiting

  • Tbilisi Heart Center LLC

    Tbilisi, Georgia · Recruiting

  • Kaohsiung Veterans General Hospital

    Kaohsiung City, Taiwan · Terminated

  • MacKay Memorial Hospital

    Taipei, Taiwan · Recruiting

  • Hualien Tzu Chi Hospital

    Hualien City, Taiwan, Taiwan · Recruiting

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    Kaohsiung City, Taiwan, Taiwan · Terminated

  • Taichung Veterans General Hospital

    Taichung, Taiwan, Taiwan · Recruiting

  • National Cheng Kung University Hospital

    Tainan, Taiwan, Taiwan · Terminated

  • National Taiwan University Hospital

    Taipei, Taiwan, Taiwan · Recruiting

  • Taipei Veterans General Hospital

    Taipei, Taiwan, Taiwan · Recruiting

  • Chang Gung Memorial Hospital - Linkou Branch

    Taoyuan City, Taiwan, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.